May 20, 2022
By Matt Hoffman
Mind Moments™, a podcast from NeurologyLive®, brings you an exclusive interview with Matthew B. Harms, MD.
May 19, 2022
By Marco Meglio
At the end of the 12-month treatment period, interseizure cluster intervals increased from 14.8 days in the first period to 35.8 days in the final 90-day stretch.
May 19, 2022
By Marco Meglio
A PK/PD model indicated that a higher concentration of nusinersen may predict an additional 5-point increase in CHOP-INTEND score beyond that observed with the approved 12-mg dose.
May 18, 2022
By Marco Meglio
In preataxia individuals, serum neurofilament levels increased with proximity to predicted ataxia onset, with significant elevations already present 5 years before onset.
May 18, 2022
By Jeremy Holden
In this episode of Connecting ALS, Dave R. Zook, JD, an advisor with expertise in federal regulatory policy, speaks to the process of making drug coverage decisions for newly approved therapies.